A self-metathesis process for the production of unsaturated dicarboxylic fatty diacids and/or unsaturated dicarboxylic fatty diesters, wherein unsaturated carboxylic fatty acids and/or esters of unsaturated carboxylic fatty acids are reacted in the presence of at least one defined ruthenium based catalyst compound. A catalyst enhancer compound selected from a sacrificial catalyst or a non-catalyst enhancer may also be used. The process exhibits improved reaction times and/or the catalyst can be used at very low concentrations.

A self-metathesis process for the production of unsaturated dicarboxylic fatty diacids and/or unsaturated dicarboxylic fatty diesters, wherein unsaturated carboxylic fatty acids and/or esters of unsaturated carboxylic fatty acids are reacted in the presence of at least one defined ruthenium based catalyst compound. A catalyst enhancer compound selected from a sacrificial catalyst or a non-catalyst enhancer may also be used. The process exhibits improved reaction times and/or the catalyst can be used at very low concentrations.

Disclosed are an o-phenyl chalcone compounds and preparation methods and uses thereof. The o-phenyl chalcone compounds are capable of inhibiting the aggregation of microtubules in tumor cells and influencing the mitosis of the cells, and has a high antitumor activity. The compounds also have inhibitory activity against proliferation on various tumor cells, such as a human ovary cancer cell A2780, a human colon cancer cell HCT8, a human breast cancer cell MCF7, a human lung cancer cell A549, a human colon cancer cell SW480, a human nasopharyngeal carcinoma cell CNE2, a human liver cancer cell HepG2 and the like at nanomole concentrations.

Disclosed are an o-phenyl chalcone compounds and preparation methods and uses thereof. The o-phenyl chalcone compounds are capable of inhibiting the aggregation of microtubules in tumor cells and influencing the mitosis of the cells, and has a high antitumor activity. The compounds also have inhibitory activity against proliferation on various tumor cells, such as a human ovary cancer cell A2780, a human colon cancer cell HCT8, a human breast cancer cell MCF7, a human lung cancer cell A549, a human colon cancer cell SW480, a human nasopharyngeal carcinoma cell CNE2, a human liver cancer cell HepG2 and the like at nanomole concentrations.

A process for producing a mixture comprising tertiary isononanoic acids proceeding from 2-ethylhexanol is characterized in that 2-ethylhexanol is (a) reacted at a temperature of 0 C. to 40 C. with a mixture of concentrated formic acid and a concentrated Brnsted acid, wherein 2 to 10 mol of formic acid are used per mole of 2-ethylhexanol and the concentrated Brnsted acid is used in an amount that corresponds to 6 to 90 mol of protons per mole of 2-ethylhexanol. The resulting reaction mixture from step (a) is subsequently (b) brought into contact with water, and the mixture comprising tertiary isononanoic acids formed according to step b) is removed.

A process for producing a mixture comprising tertiary isononanoic acids proceeding from 2-ethylhexanol is characterized in that 2-ethylhexanol is (a) reacted at a temperature of 0 C. to 40 C. with a mixture of concentrated formic acid and a concentrated Brnsted acid, wherein 2 to 10 mol of formic acid are used per mole of 2-ethylhexanol and the concentrated Brnsted acid is used in an amount that corresponds to 6 to 90 mol of protons per mole of 2-ethylhexanol. The resulting reaction mixture from step (a) is subsequently (b) brought into contact with water, and the mixture comprising tertiary isononanoic acids formed according to step b) is removed.

A process for producing a mixture comprising tertiary isononanoic acids proceeding from 2-ethylhexanol is characterized in that 2-ethylhexanol is (a) reacted at a temperature of 0 C. to 40 C. with a mixture of concentrated formic acid and a concentrated Brnsted acid, wherein 2 to 10 mol of formic acid are used per mole of 2-ethylhexanol and the concentrated Brnsted acid is used in an amount that corresponds to 6 to 90 mol of protons per mole of 2-ethylhexanol. The resulting reaction mixture from step (a) is subsequently (b) brought into contact with water, and the mixture comprising tertiary isononanoic acids formed according to step b) is removed.

A process for producing a mixture comprising tertiary isononanoic acids proceeding from 2-ethylhexanol is characterized in that 2-ethylhexanol is (a) reacted at a temperature of 0 C. to 40 C. with a mixture of concentrated formic acid and a concentrated Brnsted acid, wherein 2 to 10 mol of formic acid are used per mole of 2-ethylhexanol and the concentrated Brnsted acid is used in an amount that corresponds to 6 to 90 mol of protons per mole of 2-ethylhexanol. The resulting reaction mixture from step (a) is subsequently (b) brought into contact with water, and the mixture comprising tertiary isononanoic acids formed according to step b) is removed.

Disclosed are an o-phenyl chalcone compounds and preparation methods and uses thereof. The o-phenyl chalcone compounds are capable of inhibiting the aggregation of microtubules in tumor cells and influencing the mitosis of the cells, and have a high antitumor activity. The compounds also have inhibitory activity against proliferation on various tumor cells, such as a human ovary cancer cell A2780, a human colon cancer cell HCT8, a human breast cancer cell MCF7, a human lung cancer cell A549, a human colon cancer cell SW480, a human nasopharyngeal carcinoma cell CNE2, a human liver cancer cell HepG2 and the like at nanomole concentrations.

Disclosed are an o-phenyl chalcone compounds and preparation methods and uses thereof. The o-phenyl chalcone compounds are capable of inhibiting the aggregation of microtubules in tumor cells and influencing the mitosis of the cells, and have a high antitumor activity. The compounds also have inhibitory activity against proliferation on various tumor cells, such as a human ovary cancer cell A2780, a human colon cancer cell HCT8, a human breast cancer cell MCF7, a human lung cancer cell A549, a human colon cancer cell SW480, a human nasopharyngeal carcinoma cell CNE2, a human liver cancer cell HepG2 and the like at nanomole concentrations.